Reports Q2 revenue $53.35M, consensus $50.16M. “We are pleased to report another successful quarter with annual revenue growth of 61%. This outstanding performance across all segments of the business reflects continued focus on penetrating BPH hospitals, increasing utilization, and driving operational efficiencies across the organization,” said Reza Zadno, Chief Executive Officer. “Additionally, we achieved record gross margins of 59% and demonstrated significant operating expense leverage.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRCT:
- PROCEPT BioRobotics® Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue and EBITDA Guidance
- PROCEPT BioRobotics Announces Board Chairperson Transition
- Procept BioRobotics price target raised to $79 from $72 at Truist
- PROCEPT BioRobotics to Report Second Quarter 2024 Financial Results on August 1, 2024
- Procept Bio: AMA establishes new CPT Category I Code for Aquablation therapy